For example, CREBBP mutations have now been described in NHL (21%), DLBCL (29%), FL (32.6%), TCC (13%), ACC (7%), and relapsed ALL (18.3%), with EP300 mutations occurring slightly less frequently in NHL (7%), DLBCL (10%), FL (8.7%), TCC (13%), ACC, and relapsed ALL (Gui et al., 2011; Ho et al., 2013; Morin et al., 2011; Mullighan et al., 2011; Pasqualucci et al., 2011a). This evidence concerns the gene EP300 and acute lymphoblastic leukemia.